AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05019534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib Oral Tablet [Zelboraf]
Description: Vemurafenib 960mg qd or 960mg bid (2 cohorts)
Study NCT05019534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab Injection [Erbitux]
Description: Cetuximab 500mg/m2 Q2W
Study NCT05019534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg Q2W
Study NCT05894811 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose tolerance test
Description: Nine blood samples were collected from subjects within 4 hours of oral glucose administration, 0 min before oral glucose administration, and 10, 20, 30, 60, 90, 120, 180, 240 min afterwards, and 4 mL of venous blood was collected at each time point for glucose, C-peptide and insulin concentrations.
Study NCT05894811 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Using MRI to quantify of fat content in the liver and pancreas of the subjects
Study NCT06217003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: Preoperative application of trilaciclib during perioperative chemotherapy
Study NCT04766996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Description: Tranexamic Acid (TXA) 2 gm intraoperative
Study NCT04766996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decadron
Description: Decadron 10 mg intraoperative
Study NCT04766996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine hydrochloride
Description: Local anaesthetic 0.5% bupivacaine hydrochloride intraoperative
Study NCT05504005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection
Description: Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
Study NCT04766996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toradol
Description: Toradol nonsteroidal anti-inflammatory drug max 30 mg intraoperative
Study NCT04720300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MaaS app
Description: The MaaS App will be downloaded to students' smartphones and will provide real-time, multimodal trip planning to students on demand when they open the app.
Study NCT04720300 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No app
Description: students receive no app or housing information
Study NCT05643534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor 50 MG
Description: Participants will receive tenapanor 50 mg BID (total of 100 mg daily)
Study NCT05643534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor 25 mg bid
Description: Participants will receive tenapanor 25 mg BID (total of 50 mg daily)
Study NCT05643534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomized to receive matching placebo
Study NCT06284512 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sonography, color fundus photography
Description: Patients will undergo routine diagnostic imaging (Sonography, color fundus photography)
Study NCT05496829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Adherence Intervention
Description: The adherence intervention will be comprised of a participant preference approach in which all participants undergo a baseline pharmacist-led medication optimization session and are offered training in how to use the patient portal and freely-available smartphone reminder app.
Study NCT05496829 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Receipt of usual care from providers
Study NCT06310330 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive echocardiographic follow-up
Description: Comprehensive echocardiographic follow-up for identification of CRTCD in breast cancer patients
Study NCT06310330 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Simplified echocardiographic follow-up
Description: Simplified echocardiographic follow-up for identification of CRTCD in breast cancer patients
Study NCT05481567 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: A series of 14 questions about with the impact of periodontitis on quality of life.
Study NCT04819555 — intervention group
Intervention type: GENETIC
Intervention: Blood
Description: a blood sample will be taken during hospitalisation for diagnostic confirmation or during the quarterly multidisciplinary consultations scheduled as part of the standard follow-up set up for these patients in the ALS centres of the FILSLAN network. If the genetic status is not yet known, this sample will be taken (1 tube of 7mL EDTA) and then sent within 24-48 hours at room temperature to one of the 3 participating molecular biology laboratories according to the criteria defined in the manual of samples being taken in the 3 laboratories.
Study NCT05044455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Description: A 9 week CBT group, 2 hours weekly, is delivered by trained Peer facilitators to mothers randomized to this arm.
Study NCT04957238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ARBORea decision-making tool
Description: Online ARBORea decision-making tool will guide the use of physical restraints in ICU patients based on objective information on neurological status, level of equipment related to critical illness, and patient's family presence and involvement in patient's surveillance.
Study NCT06315465 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified Atkin's Diet with standard of care
Description: children who have given their consent and are randomized into Group I arm receives Modified Atkins Diet along with standard of care after completion of baseline investigations. Modified Atkin's Diet will be started in ratio of 1:1 and compliance is monitored by urine ketones. Followup will be done telephonically to check for compliance , adverse events at every 4 week intervals till 24 weeks.
Study NCT05819320 — intervention group
Intervention type: OTHER
Intervention: observe pattern of mucocutaneous manifestations in chronic kidney disease patients
Description: 1. To study the patterns of mucocutaneous disorders in Chronic Kidney Disease patients .~2. Comparison of the patterns of mucocutaneous manifestations and their correlation with the different stages of Chronic Kidney Disease
Study NCT05583019 — intervention group
Intervention type: DEVICE
Intervention: GENEActiv Accelerometry Device
Description: a watch like wearable sensor
Study NCT05583019 — intervention group
Intervention type: DEVICE
Intervention: Centrepoint Insights Watch (CPIW) Accelerometry Device
Description: a watch like wearable sensor
Study NCT05583019 — intervention group
Intervention type: DEVICE
Intervention: Apple Watch Accelerometry Device
Description: a watch like wearable sensor
Study NCT05583019 — intervention group
Intervention type: DEVICE
Intervention: Polysomnography
Description: Sleep monitor
Study NCT05583019 — intervention group
Intervention type: DEVICE
Intervention: Videography
Description: Thermal Camera
Study NCT06036420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flashed Light Therapy
Description: Light flashes will be presented over 60 minutes as 3-millilisecond flashes of white light at 4,000 lux every 20 seconds
Study NCT05211817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complex lifestyle intervention
Description: Volunteers will undergo a 3-month comprehensive lifestyle modification, consisting of a combined aerobic-strength training intervention, nutritional and psychological counseling. Regular examinations (body weight, waist circumference, body composition by bioimpedance) will be performed every week. Probands in the intervention and control groups will have the opportunity to participate in a long-term program of physical activity at BMC SAS after the end of the study.
Study NCT05211817 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carnosine
Description: 3 months carnosine supplementation (2 g per day) will be given in parallel with a complex lifestyle modification. Carnosine is a dipeptide of beta-alanyl l-histidine, which is found in skeletal muscle and in certain areas of the brain. It is a well-tolerated and approved food supplement in Slovakia. Scientists have extensive experience with the administration of carnosine (deCourten, Ukropcová et al, Obesity 2015 https://doi.org/10.1002/oby.21434; Schon, Ukropcova et al, 2019 DOI: 10.3390 / nu11061196 and others). Carnosine has the potential to positively affect glucose metabolism, and improve the adaptive response to exercise training interventions.
Study NCT06315465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care intervention plan will be devised for each subject which includes Behavioral therapy , Psychoeducation, Activity based interventions like attention enhancement exercises, self help skills, Occupational therapy, Pharmacotherapy, Sensory integration therapy. The parents of the children will be called telephonically every weekly to check for any issues and reinforcement to ensure appropriate regular behavioral intervention to be provided to the child. Physical follow up will be done every 4 weekly till 24 weeks.
Study NCT06315465 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of care intervention plan will be devised for each subject which includes Behavioral therapy , Psychoeducation, Activity based interventions like attention enhancement exercises, self help skills, Occupational therapy, Pharmacotherapy, Sensory integration therapy. The parents of the children will be called telephonically every weekly to check for any issues and reinforcement to ensure appropriate regular behavioral intervention to be provided to the child. Physical follow up will be done every 4 weekly till 24 weeks.
Study NCT05328752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XXB750
Description: XXB750
Study NCT05328752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05138887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin
Description: The experimental group1 was administered BH4 orally with a dose of 2 mg/kg.d, once per day, and the experimental group 2 was administered BH4 orally witha dose of 5 mg/kg.d, two times a day (If the drug dose is within the range of 151-250mg, the drug dose is 200mg) or three times a day (If the drug dose is within the range of 251-350mg, the drug dose is 300mg). The oral administration of pills was started on the same day of the first radiation treatment, and ended three months after the treatment ended.
Study NCT05138887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tetrahydrobiopterin
Description: The experimental group1 was administered BH4 orally with a dose of 2 mg/kg.d, once per day, and the experimental group 2 was administered BH4 orally witha dose of 5 mg/kg.d, two times a day (If the drug dose is within the range of 151-250mg, the drug dose is 200mg) or three times a day (If the drug dose is within the range of 251-350mg, the drug dose is 300mg). The oral administration of pills was started on the same day of the first radiation treatment, and ended three months after the treatment ended.
Study NCT05595772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Growth Factors (CGF)
Description: Application of biological membrane of Concentrated growth factor (CGF) over bone grafting and implant
Study NCT05595772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Growth Factors (PRGF)
Description: Application of biological membrane of Plasma rich in growth factors combined with Xenogeneic bone grafting material around immediate implant
Study NCT05595772 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery: Dental Implant surgery
Description: Immediate implant following extraction
Study NCT05595772 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth extraction
Description: A Traumatic tooth extraction
Study NCT05595772 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Xenogenic bone grafting
Description: Application of bovine bone grafting over area of dehiscence around immediate implant
Study NCT05825391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjustment of Antiplatelet Drugs
Description: The maximum platelet aggregation rate induced by arachidonic acid (AA-MPA)≥20%, give aspirin 200mg qd. The maximum platelet aggregation rate induced by adenosine diphosphatase (ADP-MPA)≥36.4% for flow diversion, give ticagrelor 60mg bid. ADP-MPA≥42.9% for stent-assisted coil embolization，give ticagrelor 60mg bid. ADP-MPA\<20%, give clopidogrel 37.5mg qd. The timing of drug adjustment should be at least 1 day before stent implantation, and the LTA testing should be performed again 48 hours after the drug adjustment. For patients whose ADP-MPA does not reach the normal range, a second antiplatelet drug adjustment should be performed: ticagrelor overdose: reduce to 45mg bid; ticagrelor resistance, increase to 90 mg bid.
Study NCT06036420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Videoconference-delivered Cognitive Behavioral Therapy
Description: Treatment will involve psychoeducation on sleep, circadian rhythms and light exposure, motivational interviewing, advancing of bedtime schedule, time management and coping with poor sleep, sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring for worry.
Study NCT06386835 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collagen Paste
Description: Collagen paste injection
Study NCT06386835 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mucosal advancement
Description: Mucosal advancement flap
Study NCT05670613 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CDSS Canceling
Description: The use of Clinical Decision Support System in Parenteral Nutrition
Study NCT05934877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP navigation + text messaging
Description: Using a client-centered approach, the PrEP navigator works to link participants into SUD treatment and other ancillary behavioral health and support services, according to their unique barriers, with the ultimate goal of PrEP initiation, adherence, and persistence; services may include mental healthcare, counseling for intimate partner violence, food insecurity, housing instability, hormone therapy. Text-messaging support includes once weekly text message.
Study NCT05934877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The SOC arm provides PrEP education, information, and referrals. Those randomized to the SOC arm receive an approximate 20-30-minute educational session on PrEP, and will be given a PrEP pamphlet and list of clinics that provide PrEP in LAC.
Study NCT05934877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Non-responders in the ASK-PrEP arm will be stepped and re-randomized (1:1) to Contingency Management (CM), either in concert with ASK-PrEP or alone. CM is a progressive contingency schedule. Participants submit a thrice weekly urine sample. Participants will receive a voucher-based escalating reinforcement schedule. Successive urine samples that are nonreactive for the metabolites of their identified SUD will escalate their voucher point value. Each three consecutive nonreactive urine samples will receive bonus voucher points. A reactive urine sample will place the participant at the initial voucher point value; however, a rapid reset procedure allows participants to return to their place in the escalating schedule following three consecutive nonreactive urine samples. Voucher points can be redeemed at any time during the study for goods or services that promote a pro-social and healthy lifestyle.
Study NCT05199688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab
Description: Participants will receive satralizumab treatment for a minimum of 48 weeks and then will have the opportunity to enter an optional satralizumab extension (OSE) period.
Study NCT05331794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training on BIOFIT-Park
Description: Participant will perform one strength training session on the new line of outdoor fitness equipment BIOFIT-Park. 6 machines will be used. The training will consist of 3 sets of 15-20 repetitions, working at 60-65% RM. The execution speed will be 1x1, the rest between machines will be 20 seconds and macropauses of 90 seconds between series.
Study NCT05331794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training on gym park equipament
Description: Participant will perform one strength training session on a gym park equipment. 6 machines will be used. The training will consist of 3 sets of 15-20 repetitions, working at 60-65% RM. The execution speed will be 1x1, the rest between machines will be 20 seconds and macropauses of 90 seconds between series.
Study NCT05975073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: Administered PO
Study NCT05975073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE397
Description: Administered PO
Study NCT06004830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: All participants will receive a prescription for spironolactone and will meet with a clinical pharmacist and addiction psychiatrist for further support
Study NCT06177106 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Solar Simulated Light
Description: Acute SSL will be delivered to sun damaged skin at a rate of two-times the minimal erythema dose of each individual subject. Minimal erythema dose is defined as the smallest dose of energy necessary to produce confluent erythema with four distinct borders at 22-26 hours post-exposure.
Study NCT06056245 — intervention group
Intervention type: PROCEDURE
Intervention: Preoperative step
Description: * Explanation of the surgery and use of the IV-PCA pump.~* Signed informed consent.
Study NCT06056245 — intervention group
Intervention type: DRUG
Intervention: Intraoperative
Description: Bolus of methadone 0.1mg/kg based on ideal body weight (up to a maximum dose of 20 mg), at the beginning of surgery.
Study NCT04786587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: Each pregnant woman completes the self-report during her prenatal consultation and will have a unique blood sampling for dosage of phosphatidylethanol after she returned her self-report to the practitioner and if she is included in the study (informed consent given).~the blood test for dosage of phosphatidylethanol will be offered to all eligible pregnant women in each maternity clinic of the study during the recruitment period. There will not be different arms in this study.
Study NCT05095350 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotic powder
Description: Probiotic powder containing 10 strains from Lactobacillus and Bifidobacterium genus.
Study NCT05095350 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: Placebo powder containing maltodextrin and no probiotics.
Study NCT03887221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide 50 mg
Description: Safinamide 50mg film-coated tablets will be administered to subjects in Cohort 1. The subjects will receive the tablets orally in the morning, at 8:00±1hour, under fasting conditions, with 240 mL (total volume) of still mineral water. A mouth-and-hand check will be performed immediately after dosing to ensure treatment compliance.
Study NCT05715372 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: 12-week structured program for Mediterranean diet.
Study NCT03887221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide 100mg
Description: Safinamide 100mg film-coated tablets will be administered to subjects in Cohort 2. The subjects will receive the tablets orally in the morning, at 8:00±1hour, under fasting conditions, with 240 mL (total volume) of still mineral water. A mouth-and-hand check will be performed immediately after dosing to ensure treatment compliance.
Study NCT05715372 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AHA walking program
Description: 12-week structured AHA walking program.
Study NCT05715372 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based stress reduction
Description: 8-week structured mindfulness-based stress reduction (Cabot).
Study NCT05715372 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Unstructured Mediterranean diet
Description: Unstructured 12-week program with basic outline for Mediterranean diet.
Study NCT05715372 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Unstructured walking program
Description: Unstructured 12-week walking program.
Study NCT05715372 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Unstructured stress reduction
Description: Unstructured program using mobile application for stress reduction.
Study NCT04859816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metabolic test
Description: Iv and oral administration of stable isotope tracers during fasting and a high-fat liquid mixed meal
Study NCT04859816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DXA-scan
Description: Dual energy X-ray Absorptiometry scan of whole-body fat
Study NCT04859816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRS
Description: Magnetic resonance spectroscopy of liver fat content
Study NCT04859816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feces collection
Description: 4-day feces collection